Terms & Conditions for registration

StratifyJCV testing service, fully funded by Biogen for patients who are considering or prescribed TYSABRI. StratifyJCV is validated for use with TYSARI. It allows for individualized PML risk mitigation by using anti-JCV antibody index levels and its evidence based PML risk algorithm. The PML risk estimate algorithm was developed using data from TYSABRI clinical trials and post-marketing data. Biogen has no clinical data on the PML risk associated with products other than TYSABRI. Specific questions about the JCV testing for the biosimilar natalizumab IV are best answered by your contact at the biosimilar company.

I hereby confirm that I am an HCP (healthcare professional) and I understand that these services are funded by Biogen for the testing of patients on / considering TYSABRI .